A. Stackelberg

发表

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

R. Pieters, R. Pieters, H. Dombret, 2010, Leukemia.

FLT3 mutations in childhood acute lymphoblastic leukemia at first relapse

G. Henze, K. Seeger, A. Zelmer, 2005, Leukemia.

Prognostic value of genetic alterations in children with first bone marrow relapse of childhood B-cell precursor acute lymphoblastic leukemia

Julia C. Engelmann, C. Lottaz, C. Eckert, 2013, Leukemia.

Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment

M. Schrappe, C. Bartram, C. Eckert, 2011, Leukemia.

Prevalence and prognostic significance of chromosome 21 amplifications in children with relapsed acute lymphoblastic leukemia: the ALL-REZ BFM study group

S. Mundlos, C. Eckert, G. Henze, 2010 .

Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia

G. Henze, R. Handgretinger, G. Zugmaier, 2011, Leukemia.

Results of the first randomized multicentre trial on childhood acute lymphoblastic leukaemia in Russia

G. Henze, A. Stackelberg, A. Maschan, 2008, Leukemia.

ALL-REZ BFM – The Consecutive Trials for Children with Relapsed Acute Lymphoblastic Leukemia

C. Eckert, G. Henze, A. Stackelberg, 2013, Klinische Pädiatrie.

Immunoglobulin and T-cell receptor gene rearrangements as PCR-based targets are stable markers for monitoring minimal residual disease in acute lymphoblastic leukemia after stem cell transplantation

C. Eckert, G. Henze, T. Klingebiel, 2009, Leukemia.

Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF

C. Lottaz, H. G. Einsiedel, C. Eckert, 2004, Leukemia.

Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF

C. Lottaz, H. G. Einsiedel, C. Eckert, 2004, Leukemia.

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse

C. Eckert, G. Henze, K. Seeger, 2004, Leukemia.

[Age-related characteristics of the efficacy of different glucocorticosteroids in the therapy of acute lymphoblastic leukemia].

G. Henze, G. Tallen, C. Bührer, 2015, Terapevticheskii arkhiv.

TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood

K. Seeger, T. Taube, J. Köchling, 1999, Leukemia.

Efficacy and toxicity of dexamethasone vs methylprednisolone—long-term results in more than 1000 patients from the Russian randomized multicentric trial ALL-MB 2002

G. Henze, N. Myakova, G. Tallen, 2015, Leukemia.

MRD-quantification during treatment of ETV6-RUNX1 positive ALL relapses using the genomic breakpoint of the fusion gene

C. Eckert, M. Metzler, A. Stackelberg, 2012 .

Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia

O. Haas, M. Schrappe, H. Cavé, 2016, Leukemia.

BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance

C. Eckert, S. Koschmieder, O. Heidenreich, 2016, Leukemia.